Gyre Therapeutics director Weston Claire files ownership form

GYRE THERAPEUTICS, INC. filed an initial Form 3 reporting the beneficial ownership status of director Weston Claire.

Accepted by SEC EDGAR 08/04/2026 - 08:31 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

GYRE THERAPEUTICS, INC. filed an initial Form 3 reporting the beneficial ownership status of director Weston Claire. The report lists Weston Claire as a director but shows no reported transactions or share holdings at this time. The remarks reference Exhibit 24, a Power of Attorney authorizing filings.

Key Figures

Buy transactions: 0 Sell transactions: 0 Holding entries: 0 +1 more

4 metrics

Buy transactions 0 Number of buy transactions reported for Weston Claire on this Form 3

Sell transactions 0 Number of sell transactions reported for Weston Claire on this Form 3

Holding entries 0 Total positions in GYRE stock or derivatives reported for Weston Claire

Net buy/sell shares 0 Net shares bought or sold by Weston Claire in this filing

Key Terms

Form 3, beneficial ownership, Power of Attorney, ten percent owner

4 terms

Form 3 regulatory

"filed an initial Form 3 reporting the beneficial ownership status"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership regulatory

"an initial Form 3 reporting the beneficial ownership status of director"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Power of Attorney regulatory

"The remarks reference Exhibit 24, a Power of Attorney authorizing filings"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

ten percent owner regulatory

"is_ten_percent_owner set to 0 for the reporting person"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 for GYRE show about Weston Claire?

The Form 3 reports that Weston Claire is a director of Gyre Therapeutics and currently shows no reported share holdings or insider transactions. It serves as an initial beneficial ownership statement required for certain insiders.

Are any GYRE shares bought or sold in Weston Claire’s Form 3?

No. The insider summary shows 0 shares bought and 0 shares sold, with no derivative exercises or gifts. This Form 3 only establishes Weston Claire’s status as a director, without disclosing any trading activity.

Does Weston Claire report any holdings of GYRE stock on this Form 3?

No holdings are reported. The filing indicates 0 holding entries, meaning no specific share positions are listed for Weston Claire in this initial beneficial ownership statement for Gyre Therapeutics.

Is there a Rule 10b5-1 trading plan mentioned in GYRE’s Form 3 for Weston Claire?

No. The Form 3 data show the Rule 10b5-1 indicator as null, and no footnotes describe a trading plan. The filing contains no statement that any trading plan applies to Weston Claire’s holdings.

What is the significance of the Power of Attorney in GYRE’s Form 3?

The remarks reference Exhibit 24 – Power of Attorney, which authorizes designated persons to sign and submit SEC ownership reports on Weston Claire’s behalf. It is an administrative tool to facilitate future Form 3, 4, or 5 filings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Weston Claire

(Last) (First) (Middle)

C/O GYRE THERAPEUTICS, INC.

12730 HIGH BLUFF DRIVE, SUITE 250

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/01/2026

3. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Thomas Eastling, as attorney-in-fact for Claire Weston	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)